



multimmune GmbH

263 Follower:innen

2 Wochen •

+ Folgen ...

Delighted to announce that based on the outcome of a successful Phase II clinical trial, the US Patent and Trademark Office (USPTO) has now formally granted multimmune GmbH's application for its unique natural killer (NK) cell therapy targeting tumors expressing a membrane form of heat shock protein 70 (Hsp70).

This targeted therapy does not require genetic engineering and therefore significantly simplifies and reduces the cost of NK cell-based cancer therapeutic manufacturing. Supplementing this approach is multimmune's proprietary liquid biopsy blood test for identifying patients bearing tumors expressing membrane Hsp70 (U.S. 11,460,472).

'Hsp70 Based Combination Therapy' U.S. 12,053,505 was granted on August 6, 2024.

Übersetzung anzeigen

